Kornimate/medical-research-clean huggingface dataset:
endoscopic debridement of chronic plantar fasciitis

Conditions: Fasciitis, Plantar; Fasciitis, Plantar, Chronic; Heel Spur

Summary: the aim of the study was to prospectively evaluate the results of endoscopic treatment of chronic plantar fasciitis with resection of the heel spur. treatment was assessed based on the results of clinical examinations and functional assessment as well as x-ray examination.

hypothesis: conducting research on a group of patients will prove that the use of endoscopic technique with heel spur resection for the treatment of chronic plantar fasciitis will improve the functional results of the foot. methods: patients diagnosed with chronic plantar fasciitis will undergo surgical treatment. an inspection is planned before and after 3, 6, 12, 24 and 60 months. during the check-up, the patient will undergo an x-ray examination, medical and physiotherapeutic assessment. study plan: participation in the research involves arriving at the rehasport clinic in poznań on the dates set by the chief investigator (3, 6, 12, 24 and 60 months after the surgical treatment). during the visit, members of the research team ask participants to complete a set of questionnaires, perform a medical examination with a physiotherapeutic assessment described in detail below, and an x-ray examination. the entire examination will last approximately 3 hours. 1. during all visits to rehasport clinic, the participant will be asked to complete the surveys acfas ankle and foot assessment scale. 2. during the same visits, research team members perform the following tests and examinations: 1. medical examination - aimed at assessing current ailments and range of motion, 2. x-ray examination of the foot.

Eligibility criteria:
inclusion criteria: * symptoms of chronic plantar fasciitis that have persisted for at least 6 months. despite previous conservative treatment, including corticosteroid injections, autologous prp injections, physiotherapy, use of orthoses and nsaids, * age ≥ 18 years, * written consent to participate in the study exclusion criteria: * previous foot surgery, * advanced diabetes impeding healing, * significant obesity, * contraindications to anesthesia
first-in-human single and multiple dose trial of atr-258

Conditions: Type 2 Diabetes Mellitus

Summary: this is a single-site, randomized, double-blinded, placebo-controlled, first-in-human trial, conducted in 3 parts.


Eligibility criteria:
inclusion criteria phase a and b: * participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent. * body mass index (bmi) within the range 18.5 - 29.9 kg/m2 (inclusive) at screening. * male inclusion criteria phase c: * participant must be 30 to 75 years of age inclusive, at the time of signing the informed consent. * bmi within the range 25.0 to 45.0 kg/m2 and body weight from 80 to 160 kg (inclusive) at screening. * male exclusion criteria phase c: * type 1 diabetes mellitus (t1dm) or ketosis-prone t2d based on diagnosis
locally applied pressure-induced vasodilatation

Conditions: Vascular Diseases

Summary: measure microcirculatory responses after localized ischemia obtained by local application of pressure (laser speckle).

measure microcirculatory responses after localized ischemia obtained by local application of pressure (laser speckle). the purpose of this study is to perform measurements of the methodological points made. the study will investigate : * the effect of the duration and intensity of the pressure * the reproducibility of measurements * the correlation with ischemic hyperemia post

Eligibility criteria:
inclusion criteria: * subjects without vascular pathology exclusion criteria: * pregnancy * allergy tape
pharmacokinetics of azithromycin immediate release and extended release formulation in kids with acute otitis media

Conditions: Acute Otitis Media

Summary: the purpose of this study was to determine the pharmacokinetics (pk), safety and clinical response following a single dose of either 30 mg/kg ir (immediate release) or 60 mg/kg er (extended release) formulation in pediatric subjects 6 months to 6 years of age inclusive.


Eligibility criteria:
inclusion criteria: * subjects age 6 months to \< 12 years. * have clinical signs/symptoms of acute otitis media in at least one ear. * parent(s)/legal guardian(s) provide written informed consent. exclusion criteria: * clinical significant other disease. * recent use of investigational drugs, prescription or nonprescription drugs.

Keywords: azithromycin, pharmacokinetics, pediatrics
the performance of mri prostate in men with different prostate health index (phi) values

Conditions: Prostate Cancer

Summary: this study is to investigate, in a larger cohort of consecutive men, the proportion of abnormal mri prostate in different phi ranges, and the cancer detected in chinese men with abnormal mri. this study aims to evaluate whether mri prostate can be omitted in men with lower suspicion of prostate cancer.

this is a prospective cohort study recruiting consecutive men with elevated blood test psa 4-10 ng/ml, normal prostate on digital rectal examination, and result for blood prostate health index (phi) known. a multi-parametric mri prostate with contrast will be performed in all subjects. mri prostate will be reported according to pi-rads (prostate imaging-reporting and data systems) v2.1 recommendations\[10\] and scored from 1 to 5. a pi-rads score of 3-5 is considered abnormal. the proportion of abnormal mri in different phi ranges (primary outcome) will be compared. the subjects will be offered a prostate biopsy according to usual clinical indications in our hospital: in men with phi \>35 (higher risk of significant prostate cancer), prostate biopsy (systematic biopsy, plus mri-guided if abnormal mri) will be offered. in men with phi \< 35 (lower risk of prostate cancer), prostate biopsy (systematic plus mri-guided) will be offered only if mri is abnormal.

Eligibility criteria:
inclusion criteria: * ethnically chinese men ≥18 years of age * clinical suspicion of prostate cancer and indicated for prostate biopsy * serum prostate-specific antigen (psa) 4-10 ng/ml * serum prostate health index (phi) result available * normal digital rectal examination * able to provide written informed consent exclusion criteria: * past or current history of prostate cancer * on 5-alpha reductase inhibitor in the past 6 months (e.g. finasteride, dutasteride) * mri prostate performed in past 5 years * contraindicated to undergo mri scan (e.g. pacemaker in-situ, claustrophobia, estimated glomerular filtration rate \< 50ml/min in serum renal function test within 3 months) * contraindicated for prostate biopsy (e.g. uncorrectable coagulopathy, active infection
prediction of weaning outcome from mechanical ventilation using ultrasound

Conditions: Assess the Prediction of Successful SBT and Extubation of Trachea by Bedside Lung Ultrasound in Mechanically Ventilated Patients

Summary: examine the predictive value of lung ultrasound in assessing the success of sbts and tracheal extubation among patients receiving mechanical ventilation in the intensive care unit (icu).


Eligibility criteria:
inclusion criteria: * mechanically ventilated patients will be included in the study when the underlying disease that had required intubation is considered by the attending physician as reversed and after fulfilling the criteria of weaning (alertness, and adequate gas exchange, normal ph levels, low and stable doses of vasoactive drugs, normal electrolyte levels, and a rapid shallow breathing index (rsbi) of 105 breaths per minute per liter or lower ) rendering the patient eligible to a first sbt. exclusion criteria: * exclusion criteria include patients aged \< 21yrs , patients with tracheostomy, paraplegia with medullar level above t8, cardiac arrhythmias, severe icu-acquired neuromyopathy, chronic obstructive pulmonary disease with forced expiratory volume \<50% of the theoretical predicted value, patients with planned prophylactic noninvasive ventilation after extubation, and patients who had previously failed a sbt
puraply® am plus the standard of care to standard of care alone for the management of stage ii-iv pressure ulcers.

Conditions: Chronic Pressure Ulcers

Summary: this is a prospective, multi-center, randomized, controlled clinical study of puraply® am and standard of care (soc) compared to soc alone for the management of stage ii-iv pressure ulcers located in the gluteal, ischial, hip, sacral, coccygeal, and trochanteric, malleolus, or heel area.

this study seeks to demonstrate how puraply® am performs against standard of care in stage ii-iv pressure ulcers through a prospective randomized controlled study design. subjects may be enrolled for up to 24 weeks; if healing occurs prior to week 24, a follow up healing confirmation visit shall occur two weeks later to confirm maintenance of complete wound closure and participation may continue up to 24 weeks. subjects that are randomized to the soc group have the opportunity to cross over and receive puraply am at week 12 if their index ulcer has not healed; they will then be followed for an additional 12 weeks for up to 24 weeks.

Eligibility criteria:
inclusion criteria: 1. subject must be at least 18 years of age. 2. subject has a stage ii-iv pressure ulcer located in the gluteal, ischial, hip, sacral, coccygeal, and trochanteric, malleolus, or heel area. 3. pressure ulcer should be present for 4 weeks duration and have a ulcer surface area \> 2cm2 4. if multiple ulcers are present, one ulcer must be identified as the index ulcer. 5. the index ulcer is free from active infection at the time of randomization. 6. willingness to off-load or pressure redistribute ulcer for duration of enrollment 7. the index ulcer has been offloaded for at least 7 days prior to randomization. 8. the index ulcer must have been present for at least 30 days at time of study enrollment. 9. the index ulcer is separated at least 4 cm from all other ulcers at study day -7 and study day 0 (post-debridement) and has a margin of intact skin sufficient for anchoring of the required study dressing. 10. subject has read and signed the irb/iec approved informed consent form (icf) before screening procedures are undertaken. exclusion criteria: 1. presence of signs and symptoms of infection at the index ulcer site, including but not limited to cellulitis, acute osteomyelitis, excessive exudate, gangrene or deep tissue infection 2. the index ulcer is not free of necrotic tissue and is unable to tolerate debridement 3. non-enteric or unexplored sinus tract 4. concomitant conditions that in the judgment of the investigator would make the subject inappropriate for entry to the study 5. subject has a known sensitivity to porcine materials 6. subject has a known sensitivity to polyhexamethylenebiguanide (phmb)

Keywords: chronic wounds phmb pressure ulcer wound management collagen stage ii stage iii stage iv pressure injury
intramedullary fixation for metacarpal fractures: a prospective study comparing outcomes

Conditions: Metacarpal Fracture

Summary: to prove that use of intramedullary cannulated headless hardware fixation of metacarpal fractures provides anatomic reduction, stable fixation, less operative trauma and early, active post-operative mobilization. the study compares two types of implant to determine efficacy in reduction and maintenance of reduction for fracture healing.

to prove that use of intramedullary cannulated headless hardware fixation of metacarpal fractures provides anatomic reduction, stable fixation, less operative trauma and early, active post-operative mobilization. the study compares two types of implant to determine efficacy in reduction and maintenance of reduction for fracture healing

Eligibility criteria:
inclusion criteria:patients who undergo hand surgery at university of colorado hospital and denver health medical center for surgical treatment of closed extraarticular metacarpal fracture(s). fracture classification will be based off of ao foundation/orthopaedic trauma association guidelines and radiographic interpretation * non-operative cohort: patients who underwent non-operative management of closed extra-articular metacarpal fractures at both the university of colorado and denver health medical center will also be reviewed. exclusion criteria: open metacarpal fractures (defined as any fracture associated with a laceration or break in skin continuity near the fracture site) * patients with previous history of metacarpal nonunion or malunion corrections on the affected digit * metacarpal fractures with intraarticular extension

Keywords: fractures metacrapal
evaluating the protective effect of pentoxifylline on contrast induced nephropathy

Conditions: Nephropathy

Summary: contrast induced nephropathy (cin) is of great concern when using contrast media in the new era of medicine. cin is defined as 25-50% relative increase, 0.5-1 absolute increase in serum creatinin value or 25% fall in gfr. the incidence of cin is found to be 0% to 10% in general population and up to 50% in high risk population. high risk patients include those with chronic kidney disease (gfr\<60 ml/min/1.73 m²) diabetes mellitus, congestive heart failure, anemia and advanced age. amount and kind of contrast medium and decreased circulating blood volume are other important predictors of cin. 50% of cases of cin happen within 24 hours of contrast injection. maximum creatinin levels are reached between 48-72 hours. it usually returns to previous levels in 7-10 days. suggested mechanisms are renal vasoconstriction and tubular injury. n-acetylcysteine and hydration are proved to be protective against cin and theophylline may have a role. in this study, it is hypothesized that pentoxifylline, a dimethylxanthine, can also protect renal cells from cin. it has been observed that pentoxifylline improves oxygen delivery to ischemic tissues, diminishes oxidative damage to renal tissue and may also scavenge free radicals. percutaneous coronary intervention is assumed a high risk procedure for developing cin as the amount of contrast used in pci is remarkable. therefore, the patients undergoing pci were selected for the trial. a prospective randomized trial will be conducted on patients undergoing pci.


Eligibility criteria:
inclusion criteria: * all eligible consecutive patients who are admitted to the angiography center of university hospitals for pci since april 2011 will be enrolled to enter the study. exclusion criteria: * serum creatinine above 1.5 mg/dl * frank bleeding tendency * those previously on pentoxifylline

Keywords: contrast induced nephropathy pentoxifylline pci
prolonged exposure and oxytocin

Conditions: PTSD

Summary: posttraumatic stress disorder (ptsd) is a chronic, debilitating anxiety disorder that may develop after direct or indirect exposure to traumatic events. prolonged exposure (pe) is a cognitive-behavioral psychotherapy modality with a wealth of empirical support demonstrating its efficacy to treat ptsd in a variety of populations. the neuropeptide oxytocin is a promising new pharmacotherapeutic agent with prominent anxiolytic effects . despite a strong biological and theoretical rationale for investigating the potential effectiveness of augmenting pe with intranasal oxytocin, no studies to date have done so. the current study aims to address this important gap in the literature by examining changes in ptsd symptoms following pe treatment combined with a) 40 iu of intranasal oxytocin or b) placebo.


Eligibility criteria:
inclusion criteria: 1. male or female; any race or ethnicity; age 18-75 years. 2. able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of the assessment instruments. 3. participants must be able to comprehend english. 4. meet dsm-5 criteria for current ptsd (assessed via the clinician administered ptsd scale; caps). 5. a caps score of 50 or greater. 6. participants may also meet criteria for a mood disorder (except bipolar affective disorder, see exclusion criteria) or anxiety disorders (e.g., agoraphobia, social phobia, generalized anxiety disorder). the inclusion of participants with affective and anxiety disorders is essential because of the marked frequency of the co-existence of mood and other anxiety disorders among patients with ptsd. 7. participants taking psychotropic medications will be required to be maintained on a stable dose for at least eight weeks before study initiation. initiation or change of psychotropic medications during the course of the trial may interfere with interpretation of results. exclusion criteria: 1. participants meeting dsm-5 criteria for a history of or current psychotic or bipolar affective disorders, or with current suicidal or homicidal ideation and intent. those participants will be referred clinically. 2. participants who would present a serious suicide risk or who are likely to require hospitalization during the course of the study. those participants will be referred clinically. 3. participants on maintenance anxiolytic, antidepressant, or mood stabilizing medications, which have been initiated during the past 8 weeks. 4. participants meeting dsm-5 criteria for a substance use disorder, except caffeine or nicotine, within the past 12 months. 5. pregnant women will be excluded from the proposed study.

Keywords: posttraumatic stress disorder oxytocin prolonged exposure
the interactive physical and cognitive exercise system (v3) for mild cognitive impairment (mci)

Conditions: MCI; Mild Cognitive Impairment; Alzheimer Disease; Dementia

Summary: the primary purpose of this study is to attempt to replicate and extend promising pilot findings regarding the cognitive benefits of in-home neuro-exergaming with ipaces (interactive physical and cognitive exercise system v3) for persons with mild cognitive impairment (mci). participants will include persons with mci and their co-residing partner who both exercise at home 3-5 times per week for at least 6 months and are followed through one year. all participation is "remote" (completed at home), with all equipment (pedaler, tablet, etc.) supplied directly to the home, and with all study measures completed via videoconference and mail.

a specific aim is to evaluate the potentially unique contribution of combining mental and physical exercise in an interactive way: "pedal-to-play" (ipaces), as compared with non-interactive, but simultaneous: "pedal-while-play" (pace).

Eligibility criteria:
inclusion criteria: 1. 50 years of age or older 2. co-residing study partner (spouse, adult child, roommate in same home) willing to participate in the study as an exercising participant as well 3. self or partner meets criteria for mci (per site staff/md/neuropsychologist and confirmed by study-administered montreal cognitive assessment; moca; score = between 16-26, non-inclusive; milani, 2018) 4. available for participation for one year (tablet surveys, videoconference evaluations) 5. willing and able to exercise 3-5 times per week for at least 6 months 6. can pedal an under-table elliptical 7. can read off of a small tablet screen 8. proficient in english (speaking and reading for completion of interview, surveys, game) 9. can participate in testing and read and operate tablet touch screen (adequate hearing, vision, speech) 10. written approval from primary care physician and cardiologist (if applicable) to participate in exercise for this study 11. can provide informed consent exclusion criteria: 1. already exercising at recommended levels (45 min of moderate intensity aerobic exercise 5-7x/wk) 2. significant history of cardiovascular problems 3. significant history of stroke 4. significant history of memory problems (e.g., dementia/alzheimer's) 5. significant history of other neurological condition (e.g., seizures, parkinson's, etc.) 6. tremor (idiopathic) such that would interfere with touch-screen use required throughout the study (surveys, game-play, etc.) 7. not prone to cybersickness (e.g., "car sickness" or problems with "screen time") 8. cannot provide informed consent (i.e., when phone screened with the impaired decision making capacity screen)

Keywords: adrd exercise exergame physical activity neuro-exergaming neuropsychological cognitive dual-task interactive
a study to evaluate the efficacy, safety, and tolerability of guselkumab for the treatment of participants with moderate to severe hidradenitis suppurativa (hs)

Conditions: Hidradenitis Suppurativa

Summary: the purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab in adult participants with moderate to severe hidradenitis suppurativa (hs).


Eligibility criteria:
inclusion criteria: * have moderate to severe hidradenitis suppurativa (hs) for at least 1 year (365 days) prior to the baseline visit as determined by the investigator through participant interview and/or review of the medical history * have hs lesions present in at least 2 distinct anatomic areas (examples include but are not limited to left and right axilla; or left axilla and left inguinocrural fold) * had an inadequate response to an adequate course of appropriate oral antibiotics for treatment of hs (or demonstrated intolerance to, or had a contraindication to oral antibiotics for treatment of their hs) in the investigator's opinion * have a total abscess and inflammatory nodule (an) count of greater than or equal to (\>=) 3 at the screening and baseline visit * must agree to daily use (throughout the entirety of the study) of one of the following over-the-counter treatments to the body areas affected with hs lesions: either soap and water, or a topical antiseptic wash containing chlorhexidine gluconate, triclosan, or benzoyl peroxide, or a dilute bleach bath exclusion criteria: * any other active skin disease or condition (example, bacterial, fungal or viral infection) that could have interfered with assessment of hs * has a draining fistula count of greater than (\>) 20 at the baseline visit * receipt of prescription topical therapies for the treatment of hs within 14 days prior to the baseline visit * receipt of systemic non-biologic therapies for the treatment of hs less than (\<) 4 weeks prior to the baseline visit * receipt of any oral antibiotic treatment for hs or inflammatory disorders within 4 weeks prior to the baseline visit
behavior management techniques adopted by pediatric dentists in egypt

Conditions: Child Anxiety

Summary: a cross-sectional study to investigate behavior management techniques used by pediatric dentists in egypt according to aapd clinical guidelines.

observational study to investigate behavior management techniques adopted by pediatric dentists in egypts for different patients ages, by distributing questionnaires in egyptian govermental universities consisting of participant's demographic information, behavior management techniques used for each age group and their opinion or comments.

Eligibility criteria:
inclusion criteria: * pediatric dentist and holding at least a master degree exclusion criteria: * refusal to participate